Financial Results PURE Bioscience Announces Fiscal Q2 2025 Performance
PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company,” or “we”), a pioneer in antimicrobial technology with its patented non-toxic silver dihydrogen citrate (SDC) solution, has released its financial results for the fiscal second quarter ending January 31, 2025. The Company also highlighted significant progress in its strategic initiatives, particularly in the dairy industry, reinforcing its commitment to delivering innovative and cost-effective hygiene solutions.
Financial Results – Fiscal Second Quarter 2025
PURE reported an increase in net product sales for the fiscal second quarter of 2025, reaching $391,000, compared to $325,000 in the same quarter of the previous fiscal year. This $66,000 growth represents a positive trend driven by increased sales across the Company’s expanding distribution network. The improvement reflects heightened demand for PURE’s antimicrobial solutions as businesses continue to prioritize advanced hygiene and sanitation solutions.
The Company also reported a reduction in its net loss, which amounted to $798,000 for the quarter, compared to $1,002,000 for the fiscal second quarter of 2024. This improvement was largely attributed to a $194,000 decrease in selling, general, and administrative expenses. The cost reductions were primarily driven by lower personnel expenses, a decline in professional service fees, and reduced share-based compensation expenses. Excluding share-based compensation, the Company’s net loss for the fiscal second quarter of 2025 stood at $771,000, compared to $938,000 in the prior-year period. Net loss per share remained steady at ($0.01) for both fiscal second quarters.
Financial Results – First Six Months of Fiscal 2025
For the six-month period ending January 31, 2025, PURE reported net product sales of $946,000, compared to $1,043,000 in the same period of fiscal 2024. The decrease of $97,000 was primarily due to lower sales across its end-user network, reflecting some fluctuations in market demand. Despite this decline in revenue, the Company successfully reduced its net loss to $1,487,000 for the six-month period, down from $1,737,000 in the previous year. The $386,000 reduction in selling, general, and administrative expenses played a crucial role in mitigating overall losses. Similar to the quarterly results, these cost savings were achieved through streamlined personnel costs, lower professional service fees, and reduced share-based compensation.
Excluding share-based compensation, the net loss for the six-month period was $1,403,000, an improvement from the $1,593,000 recorded in fiscal 2024. Additionally, net loss per share improved to ($0.01) for the six-month period, compared to ($0.02) in the corresponding period of the prior year. This progress underscores PURE’s ongoing efforts to enhance operational efficiency and financial stability.
CEO’s Commentary and Strategic Developments
Robert Bartlett, Chief Executive Officer of PURE Bioscience, expressed confidence in the Company’s performance and strategic direction, particularly regarding its expansion into the dairy industry. “Our fiscal second-quarter year-over-year sales growth demonstrates the progress we are making with our direct customers and distribution network,” Bartlett stated. “This quarter’s biggest accomplishment was advancing our dairy membrane solutions from microbiological laboratory bench work to the Dairy Pilot Processing Center for scale-up testing at a leading California State University and into full-scale commercial in-plant pilots.”
PURE’s entry into the dairy industry represents a critical strategic milestone, as it leverages its patented silver dihydrogen citrate (SDC) technology to address longstanding challenges in dairy processing. The Company has focused on developing and validating innovative non-oxidizing membrane cleaning solutions that enhance efficiency and reduce costs for dairy manufacturers.
Dairy Industry Innovation: Advancing Membrane Cleaning Solutions
A key highlight of PURE’s progress has been the successful pilot treatments of Ultra-Filtration (UF) and Reverse Osmosis (RO) membrane systems. These trials have been instrumental in proving the effectiveness of PURE’s proprietary antimicrobial solutions in restoring and maintaining optimal membrane performance. The positive results from these pilot treatments have generated invaluable data necessary for launching a commercial solution tailored to the dairy industry’s needs.
Membrane fouling and performance degradation are persistent challenges in dairy processing, often leading to increased water and energy consumption, higher operational costs, and reduced throughput. PURE’s innovative non-oxidizing membrane cleaning solution offers a compelling alternative to traditional cleaning methods, delivering multiple benefits:
- Water and Energy Conservation: The solution significantly reduces the amount of water and energy required for cleaning and maintenance, contributing to cost savings and sustainability efforts.
- Membrane Fouling Removal: Effective removal of fouling materials improves overall system performance and extends the lifespan of membrane filters.
- Increased Throughput: By restoring membrane functionality, the solution ensures that dairy processing operations run at peak efficiency.
- Minimized Clean-in-Place (CIP) Downtime: The new solution reduces the frequency and duration of CIP cycles, allowing dairy manufacturers to optimize productivity while maintaining strict hygiene standards.
The Company’s strategic approach includes close collaboration with distribution partners to ensure the successful implementation and adoption of its membrane cleaning solutions in real-world dairy processing environments. These partnerships will play a crucial role in scaling up commercialization efforts and securing long-term revenue growth opportunities in the dairy sector.
